Drug safety - pharmacovigilance

Drug safety (also known as pharmacovigilance), is the science of detection, assessment, understanding and prevention of side effects which allows us to understand more about the risks and benefits of a medicine. 

Discovering New Medicines

Historically, new medicines have been made from compounds found in plants, fungi and marine organisms. The molecule responsible for the medicinal properties is then extracted, identified and synthesised. Often many similar molecules are made chemically, these are called analogues. These analogues attempt to improve on the original compound to maximise desired effects and minimise unwanted effects. Now, new medicines can be made using computer aided design based on knowledge from genomics (the study of genes) and proteomics (the study of proteins).

Developing a new medicine often requires research into the mechanisms of disease. This is aided by collaboration between industry and universities or other research institutes.

Preclinical Safety

Drugs carry a number of risks and understanding the science behind adverse drug reactions can help increase the safety of new medicines. ABPI member companies work together to share knowledge and experiences in a ‘pre-competitive space’ in order to help maximise drug safety from the earliest point of developing a new medicine.

A vital part of medicines development, particularly preclinical safety research, involves the use of animals. Indeed, UK and European regulations currently require that all new medicines are tested on animals before being used in humans, to ensure patient safety.

Read more about the ABPI’s position on the use of animals in research here.

Translational Medicine

The skill of transferring research effectively from preclinical models to early clinical research in man is known as translational medicine. It also works two ways, by applying what is learnt in clinical practice to refer to clinical models. We have worked closely with NIHR in the establishment of the first Translational Research Partnerships (TRPs). These unique partnerships, run by the NIHR Office for Clinical Research Infrastructure, facilitate collaborations between industry and academia to drive translational research. There are currently two TRPs in operation: one focussing on inflammatory respiratory disease, the other on joint and related inflammatory diseases. We and our member companies continue to work closely with the TRPs to ensure they are aligned with industry, helping to translate early research to safe and effective medicines as quickly as possible.

Early stage clinical trials

Before a new medicine can be given to humans in the UK, a clinical trial application (CTA) must be approved by an agency of the Department of Health known as the Medicines and Healthcare products Regulatory Agency (MHRA). The application is reviewed by independent medical and scientific experts, who recommend whether trials can begin in humans or whether more research is required first. If a CTA is granted, a new medicine will pass through a long and complex process of early and later stage clinical studies before the company can seek authorisation to make the medicine available for doctors to prescribe for widespread use. This is if the trial shows positive data. The ABPI has produced Phase I guidance.

Read more about clinical trials.

The time, costs, and resources associated with clinical trials are very high. Clinical trial simulation is one innovative way that can improve the efficiency of clinical development. Simulation can be used across the drug development process, from informing study design, to modelling drug-drug interactions, and specific patient populations (e.g. paediatrics). We are working with our members and regulators to develop guidance on these innovative tools, such as physiologically based pharmacokinetic (PBPK) modelling.

Read our Clinical trial simulations – an essential tool in drug development publication.

Tool compounds and repurposing

The UK scored a world first in the AZ-MRC initiative that provided unprecedented access to proprietary pharmaceutical compounds for academia to use in preclinical or clinical research as tool compounds, for example to gain understanding of mechanisms of disease. In some cases, access to compounds that may have been terminated in the development process for a particular disease indication, may be explored for repurposing in another disease indication (where there is a scientific rationale) - this would save considerable time and effort in development, and open up potential avenues for new treatments.